The continuing problem of human African trypanosomiasis (sleeping sickness)
- 28 August 2008
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 64 (2) , 116-126
Abstract
Human African trypanosomiasis, also known as sleeping sickness, is a neglected disease, and it continues to pose a major threat to 60 million people in 36 countries in sub‐Saharan Africa. Transmitted by the bite of the tsetse fly, the disease is caused by protozoan parasites of the genus Trypanosoma and comes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rhodesiense and the West African form caused by Trypanosoma brucei gambiense. There is an early or hemolymphatic stage and a late or encephalitic stage, when the parasites cross the blood–brain barrier to invade the central nervous system. Two critical current issues are disease staging and drug therapy, especially for late‐stage disease. Lumbar puncture to analyze cerebrospinal fluid will remain the only method of disease staging until reliable noninvasive methods are developed, but there is no widespread consensus as to what exactly defines biologically central nervous system disease or what specific cerebrospinal fluid findings should justify drug therapy for late‐stage involvement. All four main drugs used for human African trypanosomiasis are toxic, and melarsoprol, the only drug that is effective for both types of central nervous system disease, is so toxic that it kills 5% of patients who receive it. Eflornithine, alone or combined with nifurtimox, is being used increasingly as first‐line therapy for gambiense disease. There is a pressing need for an effective, safe oral drug for both stages of the disease, but this will require a significant increase in investment for new drug discovery from Western governments and the pharmaceutical industry. Ann Neurol 2008;64:116–126Keywords
This publication has 50 references indexed in Scilit:
- Loop-Mediated Isothermal Amplification (LAMP) Method for Rapid Detection of Trypanosoma brucei rhodesiensePLOS Neglected Tropical Diseases, 2008
- Spatially and Genetically Distinct African Trypanosome Virulence Variants Defined by Host Interferon‐γ ResponseThe Journal of Infectious Diseases, 2007
- Neural–immune interactions in disorders of sleep-wakefulness organizationTrends in Neurosciences, 2007
- Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case SeriesPLOS Neglected Tropical Diseases, 2007
- Interleukin‐12p70–Dependent Interferon‐γ Production Is Crucial for Resistance in African TrypanosomiasisThe Journal of Infectious Diseases, 2007
- Treatment Failure Related to Intrathecal Immunoglobulin M (IgM) Synthesis, Cerebrospinal Fluid IgM, and Interleukin-10 in Patients with Hemolymphatic-Stage Sleeping SicknessClinical and Vaccine Immunology, 2007
- Combination Therapy for Sleeping Sickness: A Wake‐Up CallThe Journal of Infectious Diseases, 2007
- Sleeping sickness - human African trypanosomiasisPractical Neurology, 2005
- The Genome of the African Trypanosome Trypanosoma bruceiScience, 2005
- Pathogenesis of human African trypanosomiasis.2004